蛋白激酶D1在调节口腔鳞癌细胞增殖、凋亡及药物敏感性中的作用

doi:10.7518/hxkq.2019.06.003

摘要/Abstract

摘要：

目的探讨蛋白激酶D1（PKD1）在人口腔鳞癌细胞SCC-25生长、凋亡及化疗药物敏感性中的作用和机制。方法转染control-shRNA和PKD1-shRNA质粒,建立PKD1基因沉默的SCC-25细胞系;CCK-8及流式细胞术检测PKD1基因沉默后细胞的增殖、凋亡及细胞对化疗药物紫杉醇的敏感性;Western blot检测凋亡相关蛋白Bax、Bcl-2及多药耐药蛋白P-gp的表达变化。结果 PKD1在口腔肿瘤细胞SCC-25、CAL-27、SACC-83中呈现高表达;PKD1基因沉默后SCC-25细胞内抗凋亡蛋白Bcl-2表达显著降低,细胞生长受到抑制,凋亡增加;多药耐药蛋白P-gp表达下调,紫杉醇半数抑制浓度及耐药指数明显降低。结论 PKD1通过调控SCC-25细胞内凋亡相关蛋白表达和多药耐药蛋白P-gp表达,调控SCC-25生长、凋亡和对药物敏感性,是口腔鳞癌细胞生物治疗潜在靶点。

关键词: 蛋白激酶D1, 口腔鳞癌, 紫杉醇, 耐药性

Abstract:

Objective This study aimed to investigate the role of protein kinase D (PKD)1 in regulating the growth, apoptosis, and drug sensitivity of the squamous carcinoma cell line SCC-25.Methods The SCC-25 cell line was transfected with either the control-shRNA or PKD1-shRNA plasmids. The stable transfected cells were selected, and the efficiency of PKD1 knockdown was detected by Western blot. The growth and apoptosis of SCC-25 were analyzed with a cell counting kit-8 (CCK8) and flow cytometry. The 50% inhibitory concentrations (IC50) of paclitaxel in the control and PKD1 knockdown cell lines were detected by CCK-8. The expression levels of Bax, Bcl-2, and P-gp were detected by Western blot.Results PKD1 was constitutively expressed and phosphorylated in various cancer cell lines. Inhibiting the expression of PKD1 in SCC-25 cells by RNA interference could inhibit the growth and promote the apoptosis of SCC-25 cells via downregulating Bcl-2 expression. Additionally, inhibiting PKD1 expression could downregulate the expression of P-gp, thereby decreasing both the IC50 and resistance index of paclitaxel.Conclusion PKD1 plays an important role in regulating the biobehavior of SCC-25. It is a potential therapeutic target for oral squamous carcinoma.

Key words: protein kinases D1, oral squamous carcinoma, paclitaxel, multi-drug resistance

中图分类号:

Q789

王京楠,樊亚萍,陈娇,冯云,崔博淼,李小英,王利伟,陈红利,张平,吴红崑. 蛋白激酶D1在调节口腔鳞癌细胞增殖、凋亡及药物敏感性中的作用[J]. 华西口腔医学杂志, 2019, 37(6): 583-588.

Wang Jingnan,Fan Yaping,Chen Jiao,Feng Yun,Cui Bomiao,Li Xiaoying,Wang Liwei,Chen Hongli,Zhang Ping,Wu Hongkun. Role of protein kinase D1 in regulating the growth, apoptosis and drug sensitivity of oral squamous carcinoma cells[J]. West China Journal of Stomatology, 2019, 37(6): 583-588.

图/表 5

图 1

图 2

图 3

图 4

图 5

参考文献 33

[1]	Guha S, Tanasanvimon S ,Sinnett-smith J, et al. Role of protein kinase D signaling in pancreatic cancer[J]. Biochem Pharmacol, 2010,80(12):1946-1954. doi: 10.1016/j.bcp.2010.07.002 URL
[2]	Jaggi M, Du C, Zhang WG , et al. Protein kinase D1: a protein of emerging translational interest[J]. Front Biosci, 2007,12:3757-3767. doi: 10.2741/2349 URL pmid: 17485336
[3]	LaValle CR, George KM, Sharlow ER , et al. Protein kinase D as a potential new target for cancer therapy[J]. Biochim Biophys Acta, 2010,1806(2):183-192. doi: 10.1016/j.bbcan.2010.05.003 URL pmid: 20580776
[4]	Rykx A, De Kimpe L, Mikhalap S , et al. Protein kinase D: a family affair[J]. Febs Lett, 2003,546(1):81-86. doi: 10.1016/s0014-5793(03)00487-3 URL pmid: 12829240
[5]	Van Lint J, Rykx A, Maeda Y , et al. Protein kinase D: an intracellular traffic regulator on the move[J]. Trends Cell Biol, 2002,12(4):193-200. doi: 10.1016/s0962-8924(02)02262-6 URL pmid: 11978539
[6]	Rozengurt E, Rey O, Waldron RT . Protein kinase D signaling[J]. J Biol Chem, 2005,280(14):13205-13208. doi: 10.1074/jbc.R500002200 URL pmid: 15701647
[7]	Chiu TT, Leung WY, Moyer MP , et al. Protein kinase D2 mediates lysophosphatidic acid-induced interleukin 8 production in nontransformed human colonic epithelial cells through NF-kappaB[J]. Am J Physiol Cell Physiol, 2007,292(2):C766-C767. doi: 10.1152/ajpcell.00308.2006 URL pmid: 16928771
[8]	Sinnett-Smith J, Jacamo R, Kui R , et al. Protein kinase D mediates mitogenic signaling by Gq-coupled receptors through protein kinase C-independent regulation of activation loop Ser744 and Ser748 phosphorylation[J]. J Biol Chem, 2009,284(20):13434-13445. doi: 10.1074/jbc.M806554200 URL pmid: 19289471
[9]	Karam M, Bièche I, Legay C , et al. Protein kinase D1 regulates ERalpha-positive breast cancer cell growth response to 17beta-estradiol and contributes to poor prognosis in patients[J]. J Cell Mol Med, 2014,18(12):2536-2552. doi: 10.1111/jcmm.12322 URL pmid: 25287328
[10]	Sundram V, Chauhan SC, Jaggi M . Emerging roles of protein kinase D1 in cancer[J]. Mol Cancer Res, 2011,9(8):985-996. doi: 10.1158/1541-7786.MCR-10-0365 URL
[11]	Karam M, Legay C, Auclair C , et al. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway[J]. Exp Cell Res, 2012,318(5):558-569. doi: 10.1016/j.yexcr.2012.01.001 URL pmid: 22245102
[12]	Thomas H, Coley HM . Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein[J]. Cancer Control, 2003,10(2):159-165. doi: 10.1177/107327480301000207 URL pmid: 12712010
[13]	Stavrovskaya AA . Cellular mechanisms of multidrug resistance of tumor cells[J]. Biochemistry (Mosc), 2000,65(1):95-106. URL pmid: 10702644
[14]	Szakács G, Paterson JK, Ludwig JA , et al. Targeting multidrug resistance in cancer[J]. Nat Rev Drug Discov, 2006,5(3):219-234. doi: 10.1038/nrd1984 URL pmid: 16518375
[15]	Di Pietro A, Dayan G, Conseil G , et al. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships[J]. Braz J Med Biol Res, 1999,32(8):925-939. doi: 10.1590/s0100-879x1999000800001 URL pmid: 10454753
[16]	Fardel O, Lecureur V, Guillouzo A . The P-glycoprotein multidrug transporter[J]. Gen Pharmacol, 1996,27(8):1283-1291. doi: 10.1016/s0306-3623(96)00081-x URL pmid: 9304397
[17]	Abolhoda A, Wilson AE, Ross H , et al. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin[J]. Clin Cancer Res, 1999,5(11):3352-3356. URL pmid: 10589744
[18]	Juliano RL, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochim Biophys Acta, 1976,455(1):152-162. doi: 10.1016/0005-2736(76)90160-7 URL pmid: 990323
[19]	Nabekura T, Hiroi T, Kawasaki T , et al. Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein[J]. Biomed Pharmacother, 2015,70:140-145. doi: 10.1016/j.biopha.2015.01.007 URL pmid: 25776492
[20]	Yi YJ, Jia XH, Wang JY , et al. Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1[J]. Int J Mol Med, 2016,37(5):1405-1411. doi: 10.3892/ijmm.2016.2539 URL pmid: 27035504
[21]	Ren J, Xu YY, Huang QH , et al. Chabamide induces cell cycle arrest and apoptosis by the Akt/MAPK pathway and inhibition of P-glycoprotein in K562/ADR cells[J]. Anticancer Drugs, 2015,26(5):498-507. doi: 10.1097/CAD.0000000000000209 URL pmid: 25714087
[22]	Ravna AW, Sager G . Molecular modeling studies of ABC transporters involved in multidrug resistance[J]. Mini Rev Med Chem, 2009,9(2):186-193. doi: 10.2174/138955709787316065 URL pmid: 19200023
[23]	Barancík M1, Bohácová V, Kvackajová J , et al. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance[J]. Eur J Pharm Sci, 2001,14(1):29-36. doi: 10.1016/s0928-0987(01)00139-7 URL pmid: 11457647
[24]	Fujita T, Washio K, Takabatake D , et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance[J]. Int J Cancer, 2005,117(4):670-682. doi: 10.1002/ijc.21063 URL pmid: 15945097
[25]	Shen HL, Xu WL, Luo WJ , et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma[J]. Exp Hematol, 2011,39(5):558-569. doi: 10.1016/j.exphem.2011.01.013 URL
[26]	Zhao L, Wang Y, Jiang LY , et al. MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)[J]. J Exp Clin Cancer Res, 2016,35:25. doi: 10.1186/s13046-016-0300-8 URL pmid: 26842910
[27]	Yu C, Argyropoulos G, Zhang Y , et al. Neuroinflammation activates Mdr1b efflux transport through NF kappa B: promoter analysis in BBB endothelia[J]. Cell Physiol Biochem, 2008,22(5/6):745-756. doi: 10.1159/000185558 URL pmid: 19088456
[28]	Dai Y, Xie CH, Neis JP , et al. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance[J]. Head Neck, 2011,33(6):786-791. doi: 10.1002/hed.21540 URL pmid: 21560177
[29]	Kim M, Jang HR, Kim JH , et al. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion[J]. Carcinogenesis, 2008,29(3):629-637. doi: 10.1093/carcin/bgm291 URL pmid: 18283041
[30]	Guha S, Rey O, Rozengurt E . Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synjournal in human pancreatic carcinoma cell line PANC-1[J]. Cancer Res, 2002,62(6):1632-1640. URL pmid: 11912133
[31]	Brasacchio D, Alsop AE, Noori T , et al. Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization[J]. Cell Death Differ, 2017,24(6):961-970. doi: 10.1038/cdd.2016.119 URL pmid: 28060382
[32]	McCubrey JA, Steelman LS, Chappell WH , et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance[J]. Biochim Biophys Acta, 2007,1773(8):1263-1284. doi: 10.1016/j.bbamcr.2006.10.001 URL pmid: 17126425
[33]	Paolucci L, Rozengurt E . Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C[J]. Cancer Res, 1999,59(3):572-577. URL pmid: 9973202